Sidra inks research, education, children's health agreement with Great Ormond Street Hospital
Tribune News Network
Doha
Sidra Medicine, a member of Qatar Foundation, has signed a memorandum of understanding (MoU) with Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH), one of the world's leading paediatric hospitals.
The agreement focuses on collaboration across key areas of clinical service, research, and education in children's health.
The MoU was signed by Dr. Iyabo Tinubu-Karch, chief executive officer of Sidra Medicine, and Matthew Shaw, chief executive officer of GOSH, in the presence of Duncan Hill, the British Deputy Ambassador to Qatar.
The partnership outlines a multi-year framework aimed at advancing treatment pathways for rare paediatric diseases, including the development and application of gene therapies. It will also enhance joint capabilities in clinical trial design and implementation, helping to drive progress in personalised paediatric medicine.
Dr. Iyabo Tinubu-Karch, CEO of Sidra Medicine, said: 'Our MoU with Great Ormond Street Hospital reflects our forward-looking vision to integrate global expertise into localised care models. With GOSH, we are building a knowledge bridge that will enhance clinical practice and drive the next wave of paediatric innovation with measurable impact on patient care.'
The alliance will create a coordinated referral system to facilitate timely access to advanced laboratory testing, ensuring specialized care for children with complex conditions, including genetic disorders and rare diseases. This streamlined approach will also improve diagnostic efficiency and support the creation of personalized treatment plans.
Matthew Shaw, CEO of GOSH, said: 'What we are building together with Sidra Medicine will strengthen paediatric health systems for the future by leveraging expertise in clinical care, research, data and innovation, and education and training. By combining our expertise, we are not only supporting current clinicians but also laying the foundation for a more connected, resilient, and equitable model of global child health.'
Under the agreement, both institutions will roll out education and skills exchange initiatives to support the next generation of healthcare professionals. This includes pathways for physicians, nurses, allied health staff, through international fellowships, observerships, and training programmes.
Prof. Ibrahim Janahi, chief medical officer at Sidra Medicine, said: 'Sidra Medicine's partnership with GOSH creates valuable opportunities for training, fellowships, and medical education, bringing together professionals from diverse backgrounds and specialties. Our joint efforts will foster innovation, strengthen clinical skills as well as our medical education programmes.
'This will help us develop a more knowledgeable and future-ready paediatric healthcare workforce, which will also ultimately improve how we provide paediatric care services.'
The MoU with GOSH also aligns with Sidra Medicine's Clinical Trials Programme, which focuses on the development of effective treatments for paediatric rare diseases.
Prof. Khalid Fakhro, chief research officer at Sidra Medicine, said: 'Sidra Medicine's unique genetic data on Arab populations, combined with GOSH's advanced secure data environment, world-class clinical and research expertise, creates a powerful opportunity to develop region-specific diagnostic tools and clinical trials. By partnering with GOSH, Sidra Medicine aims to accelerate access to state-of-the-art therapies and expertise necessary to improve outcomes for all our patients.'
By aligning clinical pathways, innovation, education, and research and through knowledge and skills exchange, Sidra Medicine and GOSH are laying the foundation for a future where children everywhere have access to more precise, effective, and inclusive healthcare solutions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Qatar Tribune
3 days ago
- Qatar Tribune
Sidra Medicine first hospital in ME to successfully perform Intraventricular Baclofen Therapy
Tribune News Network Doha Sidra Medicine, a member of Qatar Foundation, is the first hospital in the Middle East to successfully perform two Intraventricular Baclofen Therapies. The milestone highlights Sidra Medicine's commitment to pioneering advanced neurosurgical treatments for children and young people with severe movement disorders. The procedure was performed on two young people with Dystonia. Dystonia is a neurological condition that causes uncontrolled muscle contractions. Following the procedure at Sidra Medicine, both adolescents experienced a remarkable improvement in their condition, demonstrating the effectiveness of this innovative therapy. Dr. Ian Pople, chief of Neurosurgery at Sidra Medicine, who led the procedure and emphasised its significance, said: 'The neurosurgery performed on both patients was highly successful. Unlike traditional intrathecal Baclofen therapy, which delivers the drug into the spinal fluid via a pump in the lower back, the intraventricular approach administers the medication directly into the brain's ventricles, allowing for more effective treatment of severe dystonia affecting the entire body. This approach underscores the importance of integrating neurosurgical precision with rehabilitation, ensuring patients receive the most advanced care available.' Innovative Treatment Approach Intraventricular Baclofen Therapy begins with the placement of a ventricular reservoir to allow for a trial of Baclofen therapy. This minimally invasive procedure is performed in the operating room using neuronavigational equipment, and the patient stays overnight for monitoring. Once the surgical site has healed, the patient undergoes a three-day trial in the neurosurgical ward, where an external pump delivers Baclofen similarly to the fully implanted device. Regular assessments help determine the patient's response to the medication. If the trial is successful, a permanent Baclofen pump is implanted to provide continuous therapy. The dosage is gradually adjusted to optimise symptom control, significantly improving the patient's quality of life. Qatar's First Paediatric Movement Disorders Clinic Sidra Medicine features Qatar's first paediatric-focused Movement Disorders Clinic, offering advanced care for children and young people with spasticity (uncontrollable muscle stiffness) and dystonia. The clinic takes a multidisciplinary approach, with specialists in rehabilitation medicine, neurology, neurosurgery, and therapy. It provides surgical and non-surgical interventions for patients who have not responded to medications and conventional therapy. The clinic is a key part of Sidra Medicine's commitment to pioneering pediatric neurology care. Adam's Journey: A Life Transformed Adam was one of the young patients who underwent the groundbreaking Intraventricular Baclofen Therapies at Sidra Medicine. Speaking about the impact of the treatment, Adam's mother said, 'Before the surgery, Adam's condition affected nearly every part of his day. His limbs moved constantly, making it difficult for him to concentrate, rest, or participate in school like other children his age. 'After his surgery at Sidra Medicine and thanks to the Movement Disorders Clinic, Adam's movements began to settle, and he gained a level of control we had not seen in years. These small improvements transformed how he interacts with the world. It has brought hope back into our home, and I truly believe this procedure and the supporting rehabilitative support can help many more children like Adam.' Comprehensive Neurosurgical Care at Sidra Medicine Sidra Medicine's Neurosurgery Department specialises in treating a wide range of neurological conditions, including hydrocephalus, congenital abnormalities, brain and spinal tumours, epilepsy, craniofacial disorders, and spinal conditions. The hospital's use of cutting-edge technology, combined with a patient-centred approach, ensures that children receive world-class care tailored to their individual needs. For international inquiries about Sidra Medicine's Neurosurgery services, contact
Qatar Tribune
3 days ago
- Qatar Tribune
Sidra Medicine becomes first hospital in Middle East to successfully perform Intraventricular Baclofen Therapy
DOHA: Sidra Medicine, a member of Qatar Foundation, is the first hospital in the Middle East to successfully perform two Intraventricular Baclofen Therapies. The milestone highlights Sidra Medicine's commitment to pioneering advanced neurosurgical treatments for children and young people with severe movement disorders. The procedure was performed on two young people with Dystonia. Dystonia is a neurological condition that causes uncontrolled muscle contractions. Following the procedure at Sidra Medicine, both adolescents experienced a remarkable improvement in their condition, demonstrating the effectiveness of this innovative therapy. Dr Ian Pople, Chief of Neurosurgery at Sidra Medicine, who led the procedure and emphasized its significance said: "The neurosurgery performed on both patients was highly successful. Unlike traditional intrathecal Baclofen therapy, which delivers the drug into the spinal fluid via a pump in the lower back, the intraventricular approach administers the medication directly into the brain's ventricles, allowing for more effective treatment of severe dystonia affecting the entire body. This approach underscores the importance of integrating neurosurgical precision with rehabilitation, ensuring patients receive the most advanced care available." Intraventricular Baclofen Therapy begins with the placement of a ventricular reservoir to allow for a trial of Baclofen therapy. This minimally invasive procedure is performed in the operating room using neuronavigational equipment, and the patient stays overnight for monitoring. Once the surgical site has healed, the patient undergoes a three-day trial in the neurosurgical ward, where an external pump delivers Baclofen similarly to the fully implanted device. Regular assessments help determine the patient's response to the medication. If the trial is successful, a permanent Baclofen pump is implanted to provide continuous therapy. The dosage is gradually adjusted to optimize symptom control, significantly improving the patient's quality of life. Sidra Medicine features Qatar's first pediatric-focused Movement Disorders Clinic, offering advanced care for children and young people with spasticity (uncontrollable muscle stiffness) and dystonia. The clinic takes a multidisciplinary approach, with specialists in rehabilitation medicine, neurology, neurosurgery, and therapy. It provides surgical and non-surgical interventions for patients who have not responded to medications and conventional therapy. The clinic is a key part of Sidra Medicine's commitment to pioneering pediatric neurology care. Adam was one of the young patients who underwent the groundbreaking Intraventricular Baclofen Therapies at Sidra Medicine. Speaking about the impact of the treatment, Adam's mother said: "Before the surgery, Adam's condition affected nearly every part of his limbs moved constantly, making it difficult for him to concentrate, rest, or participate in school like other children his age." "After his surgery at Sidra Medicine and thanks to the Movement Disorders Clinic, Adam's movements began to settle, and he gained a level of control we had not seen in years. These small improvements transformed how he interacts with the world. It has brought hope back into our home, and I truly believe this procedure and the supporting rehabilitative support can help many more children like Adam," she added. Sidra Medicine's Neurosurgery Department specializes in treating a wide range of neurological conditions, including hydrocephalus, congenital abnormalities, brain and spinal tumors, epilepsy, craniofacial disorders, and spinal conditions. The hospital's use of cutting-edge technology, combined with a patient-centered approach, ensures that children receive world-class care tailored to their individual needs.
Qatar Tribune
21-05-2025
- Qatar Tribune
PHCC announces the launch of ICOPE clinic at QU Health Centre
Tribune News Network Doha The Primary Health Care Corporation (PHCC) has officially announced the launch of the Integrated Care for Older People (ICOPE) Clinic at Qatar University Health Centre on Thursday, May 15, 2025, a new step forward in expanding services dedicated to the elderly population. This expansion follows the successful implementation of the service in three other health centres where the clinic is already active: Leabaib: Mondays, 8am to 1pm; Al Wajba: Wednesdays, 8am to 1pm; and Rawdat Al Khail: Thursdays, 8am to 1pm. The launch of the clinic at Qatar University Health Centre marks a significant addition, reaffirming the success of the initiative and the effectiveness of its services in supporting the health of older adults. What is the ICOPE Screening Tool? The ICOPE screening tool was developed by the World Health Organization (WHO) to address the various physiological changes associated with aging. The risks of experiencing declines in physical and mental capacities increase for older adults. In collaboration with Hamad Medical Corporation (HMC), the pilot phase of this service will be targeted at older people aged 60 and above. The clinic offers a person-centred, integrated care model managed by a multidisciplinary team. The Screening Tool Assesses: Visual impairment, hearing loss, cognitive decline and depressive symptoms, malnutrition, and mobility loss and falls. Currently, the service is available only to registered patients at Qatar University Health Centre. Eligible patients are identified and invited to undergo screening. PHCC will announce at a later stage when the service is expanded to accept referrals from all health centres. The clinic operates every Thursday from 8am to 1pm at Qatar University Health Centre.
